Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

compulsory licence

Roche - Basel

Roche boosts cancer portfolio with $1bn Blueprint deal

Collaboration will focus on the development of its ‘immunokinases’ immuno-oncology treatment

- PMLiVE

Focus on multiple myeloma treatment: Witnessing a transformation

Consultant David Cooney of Blue Latitude Health will take you through how that transformation has happened, and where the treatment of multiple myeloma is heading.

Blue Latitude Health

AZ and Roche fund PatientsLikeMe cancer patient outcomes study

The online patient network's cancer experience research will also involve M2Gen

Roche Basel Switzerland

Roche chalks up second approval for Gazyva

FDA approves additional indication as a treatment for follicular lymphoma

Bristol Myers Squibb logo

Opdivo backed for two new uses by CHMP

Recommended for additional European approvals in kidney cancer and NSCLC

- PMLiVE

New UK Cancer Drugs Fund takes shape

NICE to manage access to cancer treatments from 1 July

Eli Lilly HQ

Lilly wins European approval for lung cancer drug Portrazza

First biologic licenced in EU as a first-line treatment for adults with NSCLC

- PMLiVE

Astellas: Ten years young

Ken Jones and Sef Kurstjens on the company's progress and plans

- PMLiVE

Roche and AZ claim FDA breakthrough status for new drugs

Designation could speed up development for Roche’s ocrelizumab and AZ’s durvalumab 

- PMLiVE

Forging a path in specialty care

Takeda’s Marc Princen on the company’s plans to build a reputation in oncology, gastroenterology and vaccine

- PMLiVE

Mismanagement of Cancer Drugs Fund “unacceptable”

Influential committee of MPs finds the government still unable to assess CDF's patient benefit

Harnessing complexity

Companion diagnostics in oncology

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links